Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment
Precigen, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $4.34
+4.3% in 7d after detection
Post-detection moves
1h
—
1d
+2.6%
3d
+1.9%
7d
+4.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS